CHI3L1 Antibody

1. YKL-40 elevation significantly improved risk prediction for all-cause and cardiovascular mortality in hemodialysis patients. PMID: 28941940
2. Polymorphisms of the CHI3L1 gene (rs4950928 C>G and rs10399931 C>T) are associated with the risk and prognosis of AD and can affect the expression of CHI3L1 in plasma. PMID: 30223258
3. High YKL-40 expression is associated with endothelial cell angiogenesis in breast cancer. PMID: 29274508
4. Pretreatment serum levels of YKL-40 may be a novel prognostic factor of overall and disease-free survival in patients with nonmetastatic colorectal cancer PMID: 29642772
5. Plasma YKL-40 distinguishes between patients with features of asthma-chronic obstructive pulmonary disorder (COPD) overlap (ACO) and COPD patients. PMID: 29580282
6. CHI3L1 expression is a novel biomarker for the prognosis of gastric cancer and these findings have thus identified CHI3L1/CD44 axis as a vital pathway and potential therapeutic target in gastric cancer PMID: 30165890
7. YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients. PMID: 29357700
8. Review/Meta-analysis: YKL-40 may be implicated in bronchial inflammation and remodeling in COPD and may be considered as a useful biomarker for COPD diagnosis and monitoring. PMID: 29430175
9. YKL-40 is a glycoprotein - a potential marker for active inflammatory process - with proven predictive value in a number of diseases that evolve with inflammation, remodeling of the extracellular matrix, or development of fibrosis. PMID: 29400369
10. TMEM219 plays a critical role in Chi3l1-induced IL-13Ralpha2 mediated signalling and tissue responses. PMID: 27629921
11. Our present data reveal the crucial role of CHI3L1 in the formation of vasculogenic mimicry, which may contribute to tumour aggressiveness of cervical cancer PMID: 29452694
12. there was a negative correlation between YKL-40 and TLR4 expression in chronic sinusitis patients with nasal polyps. YKL-40 and TLR4 interacted with each other to activate NF-kappaB and promote disease progression. PMID: 29921378
13. CHI3L1 may be a previously unrecognized biomarker for diagnosing Gaucher Diseases (GD) and for evaluating the therapeutic effects of new GD drug. PMID: 29396296
14. Study established a connection between the pretreated CHI3L1 and patients with esophageal squamous cell carcinoma (ESCC), and the serum CHI3L1 was primarily secreted by ESCC-surrounded macrophages. PMID: 29209110
15. YKL-40 is expressed in cutaneous Squamous Cell Skin Cancer PMID: 30061245
16. The G allele of CHI3L1 rs4950928 might be a protective factor against the development of asthma. PMID: 29233108
17. This study suggests that CHI3L1 and CHI3L2 are associated with the progression of neurodegeneration in motor cortex and spinal cord of Amyotrophic Lateral Sclerosis patients. PMID: 28989002
18. in neurodegenerative dementias, YKL-40 is a disease-specific marker of neuroinflammation showing its highest levels in prion diseases PMID: 29126445
19. Serum IL-6, serum YKL-40, and plasma VEGF were significantly correlated with disease activity at baseline in early rheumatoid arthritis. PMID: 29336711
20. high serum YKL-40 levels correlated with the severity of obstructive sleep apnea syndrome and might serve as a nonspecific biomarker for prediction and progression of the disease. PMID: 29028081
21. YKL-40 could be considered as a useful biomarker of inflammation in psoriasis and is more sensitive than CRP or WBC. Increased YKL-40 may indicate psoriatic patients with a higher level of systemic inflammation, which may determine disease management. PMID: 28932021
22. YKL-40 protein expression associated with severe lung function impairment and severe exacerbations in Asthma patients. PMID: 29025889
23. Results suggest a potential role of chitinase 3 like 1 protein (CHI3L1) in angiogenesis in invasive ductal breast carcinoma (IDC) and may suggest its involvement in cancer progression. PMID: 29848684
24. YKL-40 is a promising biomarker for evaluating polymyositis/dermatomyositis-associated interstitial lung disease activity/severity and predicting disease prognosis. PMID: 28711881
25. Early-onset atopic dermatitis was associated with rs2303067 in SPINK5, which is involved in skin barrier functioning, and late-onset was associated with rs4950928 in CHI3L1, which is involved in the immune response. Future studies should examine the early- versus late-onset subgrouping more closely. PMID: 28681574
26. YKL-40 may represent a novel biomarker for predicting hypertension risk in prehypertension population PMID: 28797750
27. A high diagnostic sensitivity of YKL-40 in the early stages of the disease suggests the possibility of using this biomarker at an early diagnostic phase of patients with endometrial cancer. The patients with increased levels of YKL-40 before treatment are also at the higher risk of relapse. PMID: 28624692
28. Serum YKL-40 was elevated only in atrial fibrllation and not in other supraventricular arrhythmias. PMID: 28639986
29. YKL-40 is elevated in serum and bronchoalveolar lavage fluid of pulmonary alveolar proteinosis (PAP) patients, and may be of clinical utility to predict outcome in PAP PMID: 28569052
30. strongly expressed in placenta percreta and correlated with extravillous trophoblast invasion PMID: 27977409
31. YKL-40 was expressed by macrophages in liver tissue of NAFLD patients. PMID: 27739482
32. The results of this study indicate that YKL-40 may contribute to decreased stability and increased permeability of BBB in AD patients PMID: 28697565
33. YKL-40 is expressed by a subset of astrocytes in Alzheimer's disease and other tauopathies. PMID: 28599675
34. This study has shown that YKL-40 serum level is increased in patients with atopic dermatitis and reflects the severity of symptoms. PMID: 28660216
35. YKL-40 levels were found to be significantly higher in post-infectious bronchiolitis obliterans (PIBO) patients with exacerbation compared with that in bronchiolitis patients and showed a positive correlation with the severity of disease before diagnosis of PIBO. PMID: 28567534
36. miR-24 serves as a molecular regulator in S. aureus-induced macrophage polarization through targeting of CHI3L1 and regulation of the MAPK pathway PMID: 28303416
37. High YKL-40 expression is independently and markedly associated with worse overall survival in glioblastoma patients. PMID: 27090900
38. Datashow that patients with YKL-40 overexpression had significantly shorter survival time than those with low YKL-40 expression. PMID: 28099248
39. The level of serum YKL-40 is a significant and independent biomarker to predict the clinical outcome in large-artery atherosclerotic stroke. PMID: 27650381
40. TrkB-containing exosomes play a key role in the control of glioblastoma progression and aggressiveness, as seen in a model of YKL-40-inactivated glioblastoma cells PMID: 27385098
41. findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens PMID: 29324810
42. The present meta-analysis indicate that elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. YKL-40 may serve as a promising predictive biomarker of prognosis of breast cancer PMID: 28036271
43. YKL-40 induces IL-18 production in osteoblasts and thereby stimulates angiogenesis of endothelial progenitor cells through the suppression of miR-590-3p via the focal adhesion kinase (FAK)/PI3K/Akt signaling pathway. PMID: 28448439
44. YKL-40 levels showed a positive correlation with blood neutrophil counts but no consistent relationships with clinical characteristics of relevance to continuous wheeze in preschool children PMID: 27732738
45. Study suggests that YKL-40 is associated with hypertension incidence only among men. PMID: 27815265
46. In HCT donors with YKL-40 plasma concentrations, a trend toward increased grade II-IV acute GvHD in recipients was observed with no significant associations with overall survival, treatment-related mortality or relapse PMID: 27427920
47. Review of evidence for the role of YKL-40 in the diagnosis, prognosis and cause of cardiovascular and alcoholic liver disease. PMID: 27187575
48. the level of CHI3L1 protein in the sera of patients with gastric or breast cancer was significantly elevated compared with those of healthy donors. M2 macrophage-secreted CHI3L1 promoted the metastasis of gastric and breast cancer cells in vitro and in vivo PMID: 28143526
49. Besides being associated with tau pathology, CSF YKL-40 adds to the growing array of biomarkers reflecting distinct molecular brain mechanisms potentially useful for stratifying individuals for biomarker-guided, targeted anti-inflammatory therapies emerging from precision medicine. PMID: 28281838
50. SNPs in CHI3L1 and cord blood YKL-40 were not associated with lung function measurements at 5 weeks and 6 years, respiratory symptoms in the first year, and allergic sensitisation at 6 years. Genetic variation in CHI3L1 might be related to the development of milder forms of asthma. PMID: 27193312

Show More

Hide All

HGNC: 1932

OMIM: 181500

KEGG: hsa:1116

STRING: 9606.ENSP00000255409

UniGene: Hs.382202